Guidelines for laboratory monitoring of treatment of persistent virus infections

D Pillay; V C Emery; D Mutimer; M M Ogilvie; W Carman; K Mutton; T Wreghitt; D Westmoreland; J Breuer; M Zuckerman; Public Health Laboratory Service Advisory Committee on Virology

doi:10.1016/s1386-6532(02)00018-5

Guidelines for laboratory monitoring of treatment of persistent virus infections

J Clin Virol. 2002 Jul;25(1):73-92. doi: 10.1016/s1386-6532(02)00018-5.

Authors

D Pillay¹, V C Emery, D Mutimer, M M Ogilvie, W Carman, K Mutton, T Wreghitt, D Westmoreland, J Breuer, M Zuckerman; Public Health Laboratory Service Advisory Committee on Virology

Affiliation

¹ PHLS Antiviral Susceptibility Reference Unit, Department of Immunity and Infection, University of Birmingham Medical School, Edgbaston, B15 2TT, Birmingham, UK

PMID: 12126724
DOI: 10.1016/s1386-6532(02)00018-5

Abstract

A growing number of antiviral agents are available for treatment of persistent viral infections. This has increased the requirement for virology laboratories to undertake sophisticated assays for monitoring the efficacy of treatment and identifying drug failure at an early stage. The consensus guidelines within this article address the laboratory requirements for monitoring treatment of the herpes viruses, HIV-1, Hepatitis B and Hepatitis C.

MeSH terms

Chickenpox / drug therapy
Chickenpox / virology
Clinical Laboratory Techniques / standards*
Cytomegalovirus Infections / drug therapy
Cytomegalovirus Infections / virology
HIV Infections / drug therapy
HIV Infections / immunology
HIV Infections / virology
HIV-1
Hepatitis B / drug therapy
Hepatitis B / virology
Hepatitis C / drug therapy
Hepatitis C / virology
Herpes Simplex / drug therapy
Herpes Simplex / virology
Humans
Laboratories
Laboratories, Hospital / standards*
Medical Laboratory Personnel*
Practice Guidelines as Topic*
Virus Diseases / diagnosis*
Virus Diseases / drug therapy
Virus Diseases / virology
Virus Latency*